Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last ¥5,290 JPY
Change Today -30.00 / -0.56%
Volume 116.0K
4516 On Other Exchanges
As of 1:00 AM 11/27/15 All times are local (Market data is delayed by at least 15 minutes).

nippon shinyaku co ltd (4516) Snapshot

Previous Close
Day High
Day Low
52 Week High
11/19/15 - ¥5,430
52 Week Low
11/28/14 - ¥3,400
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for NIPPON SHINYAKU CO LTD (4516)

Related News

No related news articles were found.

nippon shinyaku co ltd (4516) Related Businessweek News

No Related Businessweek News Found

nippon shinyaku co ltd (4516) Details

Nippon Shinyaku Co., Ltd. manufactures and sells pharmaceuticals and foodstuffs in Japan. It operates in two segments, pharmaceuticals and Functional Food. The company offers drugs for pain, inflammation, and allergies; hematologic malignancies; urological diseases; gastrointestinal disorders; cardiovascular and metabolic diseases; and other diseases. Its products include Tramal for cancer and chronic pain; Erizas, a dry powder inhaler for allergic rhinitis; Azunol Gargle liquid; Baynas, a remedy for allergic rhinitis; Livostin for allergic rhinitis and conjunctivitis; Hypen, a non-steroidal anti-inflammatory and analgesic agent; Zalutia for urinary disorder caused by benign prostatic; Cialis for erectile dysfunction; Eviprostat for prostatic hypertrophy; Bladderon for pollakisuria; Estracyt for prostate cancer; Vidaza for myelodysplastic syndrome; Cylocide for solid tumor and acute leukemia; Trisenox for relapsed and refractory acute promyelocytic leukemia; and Amnolake for relapsed and refractory acute promyelocytic leukemia. The company’s products also include Gaslon N for gastric ulcer and gastritis; Portolac, an antihyperammonemia agent; Adcirca for pulmonary arterial hypertension; Selectol, a vasodilating beta-1 blocker; Regtect for maintaining alcohol abstinence; Lunabell for dysmenorrhea; and Cephadol for vertigo. The company is also involved in the research and development, and marketing of drugs in the areas of urology, hematology, gynecology, otolaryngology, and orthopedics. In addition, it provides functional foods, including health food ingredients, preservatives/shelf life improvers, protein preparations, and spice and condiments. The company was founded in 1911 and is headquartered in Kyoto, Japan.

1,812 Employees
Last Reported Date: 06/29/15
Founded in 1911

nippon shinyaku co ltd (4516) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

nippon shinyaku co ltd (4516) Key Developments

Nippon Shinyaku Co. Ltd. Reports Consolidated Earnings Results for the Six Months Ended September 30, 2015; Provides Earnings Guidance for the Year Ending March 31, 2016

Nippon Shinyaku Co. Ltd. reported consolidated earnings results for the six months ended September 30, 2015. For the period, the company reported net sales of JPY 39,413 million against JPY 82,381 million a year ago. Operating income was JPY 2,110 million against JPY 2,303 million a year ago. Ordinary income was JPY 2,335 million against JPY 2,272 million a year ago. Net income attributable to owners of parent was JPY 1,523 million or JPY 22.61 per basic share against JPY 1,440 million or JPY 21.37 per basic share a year ago. Income before income taxes and minority interests was JPY 2,335 million against JPY 2,272 million a year ago. Net cash used in operating activities was JPY 271 million against net cash provided by operating activities of JPY 1,690 million a year ago. Purchase of tangible fixed assets was JPY 369 million against JPY 387 million a year ago. Purchase of intangible assets was JPY 76 million against JPY 70 million a year ago. The company provided earnings guidance for the year ending March 31, 2016. For the period, the company expects operating net sales of JPY 87,000 million, operating income of JPY 9,300 million, ordinary income of JPY 9,500 million and net income attributable to owners of parent of JPY 6,700 million or JPY 99.45 per share.

Nippon Shinyaku Co. Ltd., Q2 2016 Earnings Call, Nov 10, 2015

Nippon Shinyaku Co. Ltd., Q2 2016 Earnings Call, Nov 10, 2015

Nippon Shinyaku Co. Ltd. to Report Q2, 2016 Results on Nov 06, 2015

Nippon Shinyaku Co. Ltd. announced that they will report Q2, 2016 results on Nov 06, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4516:JP ¥5,290.00 JPY -30.00

4516 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actelion Ltd SFr.142.90 CHF +0.30
United Therapeutics Corp $154.26 USD -1.25
View Industry Companies

Industry Analysis


Industry Average

Valuation 4516 Industry Range
Price/Earnings 58.4x
Price/Sales 4.2x
Price/Book 3.4x
Price/Cash Flow 55.6x
TEV/Sales 4.0x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact NIPPON SHINYAKU CO LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at